Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).
Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW. Rider LG, et al. Among authors: herbelin l. Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11(0 11):S118-57. doi: 10.1002/acr.20532. Arthritis Care Res (Hoboken). 2011. PMID: 22588740 Free PMC article. Review. No abstract available.
Pilot trial of etanercept in the treatment of inclusion-body myositis.
Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, Mendell JR. Barohn RJ, et al. Among authors: herbelin l. Neurology. 2006 Jan 24;66(2 Suppl 1):S123-4. doi: 10.1212/01.wnl.0000192258.32408.54. Neurology. 2006. PMID: 16432140 Clinical Trial.
Targeting protein homeostasis in sporadic inclusion body myositis.
Ahmed M, Machado PM, Miller A, Spicer C, Herbelin L, He J, Noel J, Wang Y, McVey AL, Pasnoor M, Gallagher P, Statland J, Lu CH, Kalmar B, Brady S, Sethi H, Samandouras G, Parton M, Holton JL, Weston A, Collinson L, Taylor JP, Schiavo G, Hanna MG, Barohn RJ, Dimachkie MM, Greensmith L. Ahmed M, et al. Among authors: herbelin l. Sci Transl Med. 2016 Mar 23;8(331):331ra41. doi: 10.1126/scitranslmed.aad4583. Sci Transl Med. 2016. PMID: 27009270 Free PMC article.
Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis.
Ramdharry G, Morrow J, Hudgens S, Skorupinska I, Gwathmey K, Currence M, Herbelin L, Jawdat O, Pasnoor M, Mcvey A, Barohn RJ, Burns TM, Dimachkie MM, Amato AA, Hanna MG, Machado PM. Ramdharry G, et al. Among authors: herbelin l. Muscle Nerve. 2019 Aug;60(2):161-168. doi: 10.1002/mus.26521. Epub 2019 Jun 7. Muscle Nerve. 2019. PMID: 31107564
Reliability testing of the quantitative myasthenia gravis score.
Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Barohn RJ, et al. Among authors: herbelin l. Ann N Y Acad Sci. 1998 May 13;841:769-72. doi: 10.1111/j.1749-6632.1998.tb11015.x. Ann N Y Acad Sci. 1998. PMID: 9668327 No abstract available.
Myasthenia gravis activities of daily living profile.
Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Wolfe GI, et al. Among authors: herbelin l. Neurology. 1999 Apr 22;52(7):1487-9. doi: 10.1212/wnl.52.7.1487. Neurology. 1999. PMID: 10227640
79 results